A study published in The New England Journal of Medicine has reported that the oral peptide icotrokinra, a selective ...
The global psoriasis treatment market is projected to expand at a compound annual growth rate (CAGR) of 8.5% by 2026. Key factors fueling this growth include the rising prevalence of psoriasis, ...
Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical ...
Investing.com -- Arcutis Biotherapeutics Inc (NASDAQ:ARQT) stock rose 4.5% on Monday after the FDA accepted the company’s application to expand the use of its psoriasis treatment to younger children.
Once-daily, steroid-free topical foam intentionally formulated to help manage psoriasis across difficult-to-treat areas of ...
A novel oral therapy that inhibits the interleukin-23 inflammatory pathway provided control of moderate-to-severe psoriasis ...
The sNDA was supported by data from a 4 week MUSE study and a long-term open-label study in children aged 2 to 5 years.
Biologic therapy use among patients with psoriatic disease was associated with a lower risk for malignancy compared with topical therapy use.
Significant rates of depression, anxiety, and sleep disturbances in patients with psoriatic arthritis (PsA) and palmoplantar psoriasis (PPP) were identified, underscoring the need for integrated ...
Everyday Health on MSN
7 Psoriasis Myths and the Facts That Debunk Them
Discover key truths about psoriasis, from symptoms and causes to effective management strategies to improve your quality of ...
Researchers reviewed hormone variation, life cycles, and their effect on quality of life specific to women with psoriasis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback